Revision History
Facilities must conduct ongoing medical audits of stereotactically-guided breast biopsy procedures to evaluate and improve performance. At a minimum, the physician should be able to provide the number of procedures done by type, the number of cancers diagnosed and the number of complications requiring treatment. The ACR will request the following audit data as part of the application process:
Total number of procedures
Total number of cancers found
Total number of benign lesions
Total number of stereotactic biopsies needing repeat biopsy, categorized by reason and type of biopsy (i.e., CNB, FNAC):
Reason for Repeat Biopsy | Data |
Insufficient Sample |
|
Discordance |
|
Cellular Atypia, Radial Scar |
|
Other |
|
Complications requiring treatment, categorized by type of biopsy (i.e., CNB, FNAC)
Total number
Number with hematoma (requiring intervention)
Number with infections requiring treatment
Number of other complications
Submit your facility’s patient volume and outcome data from the past 12 months into your online testing package. If you are a new facility, submit all the patient volume and outcome data you have available.
A peer review program is not required for stereotactic breast biopsy accreditation, as applicants must already submit biopsy outcome data described above.
Revision History for this Article | ||
Date | Section | Description of Revision(s) |
12-12-19 | All | Article created; FAQs incorporated; No criteria changes |
Previous: QC: Stereotactic Breast Biopsy | Next: Special Cases in Stereotactic Breast Biopsy QC |